INTRODUCTION
============

Skin cancer is among the most common cancers with a rapidly increasing incidence worldwide \[[@b1-kjim-2019-218]-[@b7-kjim-2019-218]\]. Ultraviolet (UV) exposure is an established risk factor for skin cancer. The incidence rate of skin cancer highly depends on skin phenotype and geographic variations, which determine the amount of UV reaching the papillary dermis and is much lower in Asians compared to Caucasians \[[@b3-kjim-2019-218]-[@b5-kjim-2019-218],[@b8-kjim-2019-218]-[@b14-kjim-2019-218]\]. Therefore, several factors, including ethnic and geographic variation, must be considered when interpreting data associated with skin cancer.

Hydrochlorothiazide (HCTZ) is the one of the most commonly prescribed diuretic and antihypertensive agents and the first-line treatment in hypertensive disorder \[[@b15-kjim-2019-218]\]. HCTZ exhibits known photosensitizing properties and recent studies reported that the use of HCTZ was associated with an increased risk of non-melanoma skin cancer (NMSC; including squamous cell carcinoma \[SCC\] and basal cell carcinoma \[BCC\]), melanoma, Merkel cell carcinoma, and malignant adnexal skin tumors \[[@b16-kjim-2019-218]-[@b20-kjim-2019-218]\]. In November 2018, the Medicines and Healthcare Products Regulatory Agency in the UK informed that HCTZ is associated with the risk of NMSC, particularly in long-term use. However, some studies have questioned this correlation and whether HCTZ increases the risk of skin cancer has been controversial \[[@b21-kjim-2019-218]-[@b23-kjim-2019-218]\]. In addition, no studies have examined HCTZ use and the risk of skin cancer in an Asian population. The inconsistent results and limited data in an Asian population inspired us to conduct a nationwide study on the association between HCTZ use and the risk of skin cancer in a South Korean population.

METHODS
=======

Study population and data collection
------------------------------------

This study is a population-based retrospective cohort study that used claims data of the Health Insurance Review and Assessment Service (HIRA) using the Korean Classification of Disease 8th revision (KCD-8) codes, which are similar to the 10th revision of International Classification of Diseases (ICD-10) codes, from January 1, 2007 through June 30, 2017. In South Korea, approximately 98% of the Korean population is eligible to receive healthcare coverage under the National Health Insurance Service (NHIS), and the HIRA is the repository for NHIS data \[[@b24-kjim-2019-218]\]. HIRA provides national records of the number of hospital visits, prescription drugs, and diagnosis of diseases in all covered inpatients and outpatients. Cancer diagnosis can be registered only after the diagnosis is confirmed by pathologic examination. Therefore, claims data from HIRA, especially cancer diagnosis, are considered reliable. Because of the homogeneity of the study population, data on race/ethnicity have not been collected. This study was approved by the Institutional Review Board at Veterans Health Service medical center, Seoul, South Korea (IRB number: 2018-03-025). The IRB approved a waiver of written informed consent for retrospective deidentified patient data. The stepwise approach for patient selection is summarized in [Fig. 1](#f1-kjim-2019-218){ref-type="fig"}. We generated a cohort of hypertensive patients (n = 3,949,082) satisfying all of the following: (1) patients with a first diagnosis of essential (primary) hypertension (KCD-8 or ICD-10 code for I10) between January 1, 2009 and December 31, 2016; (2) patients who received at least three prescriptions for any antihypertensive drug after diagnosis of I10; and (3) patients who were over 18 years old at the time of diagnosis of hypertension. We excluded patients who were diagnosed in 2007 to 2008, prior to the registry date, with the following: (1) skin cancers (C43, C44, D03, D04); (2) other malignant neoplasms (C01 to C26, C30 to C34, C37 to C41, C45 to C58, C60 to C86, C88, C90 to C97); (3) essential (primary) hypertension (I10); and (4) human immunodeficiency virus (B20 to B24). We also excluded patients who underwent the following between January 1, 2007 and June 30, 2017: (1) organ transplantation (T86, Z94); (2) ≥ 6 months administration of immunosuppressant agents (cyclosporine A, azathioprine, mycophenolate mofetil); and (3) had been diagnosed with skin cancer prior to the diagnosis of hypertension. NMSC was defined as ICD-10 code of "C44" (Other malignant neoplasm of skin) and "D04" (Carcinoma *in situ* of skin), and melanoma was defined as "C43" (Malignant melanoma of skin), and "D03" (Melanoma *in situ*). The hypertensive patient cohort was divided into those who were treated with HCTZ ("HCTZ-users") and those treated with antihypertensive agents other than HCTZ ("non-HCTZ-users"). In both groups, we obtained baseline demographic information, including patient age at the time of cohort registry, sex, comorbidities using Charlson comorbidity index (CCI) scores, concurrent use of photosensitizing drugs (tetracyclines, hydroxychloroquine, oral retinoids, antibiotics, photosensitizing antihypertensive drugs, non-steroidal anti-inflammatory drugs \[NSAIDs\], other diuretics), and other drugs potentially affecting skin cancer (aspirin, systemic corticosteroids, statins).

Assessment of exposure
----------------------

Follow-up was initiated on the first day of the administration of antihypertensive agents and ended on June 30, 2017 or at the time of first diagnosis with skin cancer. We defined the date of the end of follow-up as the index date. "HCTZ-users" were defined as patients having at least three prescriptions for HCTZ and "non-HCTZ-users" were defined as patients never prescribed for HCTZ during the follow-up period. We also investigated cumulative doses and duration of HCTZ. We also divided HCTZ users into "low users" as \< 50,000 mg and "high users" as ≥ 50,000 mg. Cumulative doses of HCTZ were also categorized into quartiles as follows (NMSC/melanoma): Quartile 1 (3.125 to 2,699.99 mg/3.125 to 2,699.99 mg), Quartile 2 (2,700.0 to 7,268.74 mg/2,700.0 to 7,274.99 mg), Quartile 3 (7,268.75 to 16,487.49 mg/7,275.00 to 16,499.99 mg), and Quartile 4 (16,487.50 to 8,332,212.5 mg/16,500.00 to 8,332,212.5 mg). Exposure to other drugs was also defined as at least 3 prescriptions for each drug.

Covariates
----------

We included covariates as follows: (1) age; (2) sex; (3) CCI scores (0, low; 1 to 2, medium; ≥ 3, high); (4) use of photosensitizing drugs included as follows: ① tetracyclines (doxycycline, tetracycline), ② antimalarials (hydroxychloroquine), ③ oral retinoids (acitretin, isotretinoin), ④ antibiotics (ciprofloxacin, levofloxacin, trimethoprim/sulfamethoxazole), ⑤ NSAIDs (ibuprofen, naproxen, piroxicam, diclofenac, celecoxib), ⑥ other diuretics (amiloride, azosemide, furosemide, torasemide, xipamide, chlorthalidone, indapamide, spironolactone), ⑦ photosensitizing antihypertensive drugs (angiotensin converting enzyme inhibitors \[enalapril, ramipril, temocapril\], calcium channel blockers \[amlodipine, lercanidipine, nifedipine, diltiazem, verapamil, gallopamil\], angiotensin II receptor blockers \[valsartan, losartan, olmesartan, telmisartan, candesartan, fimasartan\], beta-blockers \[carvedilol, atenolol\]), and ⑧ hypoglycemics (glimepiride, glibenclamide, gliclazide); and (5) the use of other drugs potentially affecting skin cancer as follows: ① antiplatelet agent (aspirin), ② systemic glucocorticoid (hydrocortisone, methylprednisolone, triamcinolone), and ③ statins (simvastatin, lovastatin, atorvastatin).

Statistical analysis
--------------------

Continuous variables were expressed as means ± standard deviations (SD). Categorical variables were expressed as frequencies or percentages. The Student *t* test for continuous variables and chi-square test for categorical variables were used to compare characteristics of study subjects. The incidence rates were presented as events per 100,000 patient-years (PY) with exact Poisson confidence intervals of 95%. Associations of exposure to HCTZ and skin cancer were summarized with hazard ratios (HRs) and 95% confidence intervals, estimated with Cox proportional model adjusted age, sex, and CCI score. Fully adjusted model additionally adjusted for (1) concurrent use of photosensitizing drugs (tetracyclines, hydroxychloroquine, oral retinoids, antibiotics, photosensitizing antihypertensive drugs, NSAIDs, other diuretics); and (2) concurrent use of drugs potentially affecting skin cancer (aspirin, systemic corticosteroids, statins). To evaluate effects of the cumulative duration and dose-response relationship between HCTZ and skin cancer, the HRs were individually calculated by the lowest dose (\< 10,000 mg and Quartile 1) and the shortest duration (\< 1 year) groups of HCTZ as references. All statistical analyses in this study were performed using statistical program R version 3.4.1. (The R Foundation for Statistical Computing, Vienna, Austria) and SAS version 9.3 (SAS Institute, Cary, NC, USA). A *p* \<0.05 was considered to be statistically significant.

RESULTS
=======

Relation of exposure to HCTZ and the risk of NMSC
-------------------------------------------------

A total of 1,327,256 HCTZ-users and 1,851,362 non-HCTZ-users were included in this study. The mean age ± SD of HCTZ-users and non-HCTZ-users were 55.8 ± 12.7 and 55.1 ± 12.9 years, respectively. The 50 to 64 year old group was predominant in both groups (41.6% in HCTZ-users and 43.2% in non-HCTZ-users). HCTZ-users had a statistically higher proportion of females compared with the non-HCTZ users (*p* \< 0.001). Both groups had a tendency to have more comorbidities with high CCI scores (≥ 3), corresponding to 64.4% of HCTZ-users and 59.7% of non-HCTZ-users. Concurrent use of photosensitizing drugs and other drugs potentially affecting skin cancer is described in detail in [Table 1](#t1-kjim-2019-218){ref-type="table"}. As more than 80 photosensitizing drugs were administered simultaneously in the hypertensive patient cohorts, only a few drugs are listed in [Table 1](#t1-kjim-2019-218){ref-type="table"} in order of frequency.

NMSC developed in 2,115 and 2,811 HCTZ-users and non-HCTZ users, respectively. The incidence rate of NMSC was 28.04 per 100,000 PY among HCTZ-users and 33.64 per 100,000 PY among non-HCTZ-users, yielding an age-, sex-, and comorbidities-adjusted HR of 0.72 (95% CI, 0.68 to 0.77; *p* \< 0.001) and fully-adjusted HR of 0.96 (95% CI, 0.91 to 1.02; *p* = 0.236). High HCTZ-users (≥ 50,000 mg of cumulative doses) had fully-adjusted HR of 0.22 (95% CI, 0.11 to 0.42) in NMSC compared with non-HCTZ-users ([Table 2](#t2-kjim-2019-218){ref-type="table"}). Clear cumulative dose-response and duration-response relationships were observed in increasing exposure of HCTZ in NMSC (*p* trend \< 0.001) ([Table 3](#t3-kjim-2019-218){ref-type="table"} and [Fig. 2](#f2-kjim-2019-218){ref-type="fig"}).

Relation of exposure to HCTZ and the risk of melanoma
-----------------------------------------------------

A total of 1,327,673 HCTZ-users and 1,851,362 non-HCTZ users was included in this study. Other characteristics of study subjects are described in detail in [Table 1](#t1-kjim-2019-218){ref-type="table"}. Melanoma developed in 460 and 706 HCTZ-users and non-HCTZ-users, respectively. Age-, sex-, and comorbidities-adjusted HR was 0.63 (95% CI, 0.56 to 0.71; *p* \< 0.001), and fully-adjusted HR was 0.85 (95% CI, 0.75 to 0.97; *p* = 0.016). High HCTZ users (≥ 50,000 mg of cumulative doses) had HRs of 0.20 (95% CI, 0.05 to 0.79; *p* = 0.022) in melanoma compared with non-HCTZ users ([Table 2](#t2-kjim-2019-218){ref-type="table"}). Clear cumulative dose-response and duration-response relationships were observed in increasing exposure of HCTZ in melanoma (*p* trend \< 0.001) ([Table 3](#t3-kjim-2019-218){ref-type="table"} and [Fig. 2](#f2-kjim-2019-218){ref-type="fig"}).

DISCUSSION
==========

In this large, population-based, retrospective study, we found that the risk of melanoma was significantly reduced in HCTZ-users compared with non-HCTZ-users (HR, 0.85; 95% CI, 0.75 to 0.97; *p* = 0.016) and the risk of NMSC was slightly reduced, but no significance was observed (HR, 0.96; 95% CI, 0.91 to 1.02; *p* = 0.236). High cumulative doses (≥ 50,000 mg and cumulative doses of ≥ quartiles 3) of HCTZ were significantly associated with decreased risk for both melanoma and NMSC. We also found clear cumulative dose-response and duration-response relationships between HCTZ and both NMSC and melanoma (*p* trend \< 0.001). This study showed a decreased risk of skin cancer with the cumulative dose of HCTZ. Notably, our results are different than previous studies that reported an increased risk or no associated risk of skin cancer with the use of HCTZ.

Antihypertensive drugs are usually continuously administered for the treatment of chronic conditions \[[@b15-kjim-2019-218]\]. Many of these drugs are classified as photosensitizers, which can trigger phototoxic or photoallergic reactions \[[@b21-kjim-2019-218]-[@b23-kjim-2019-218],[@b25-kjim-2019-218]-[@b29-kjim-2019-218]\]. Several concerns have been raised regarding the association of these drugs with increased skin cancer risk. Recently, based on two recent pharmacoepidemiological case-control studies from Denmark, the European Medicines Agency warned that long-term use of HCTZ may increase the risk of NMSC and recommended regular checks for any suspicious skin lesions or moles \[[@b30-kjim-2019-218]\]. In these two Danish studies, Pedersen et al. \[[@b19-kjim-2019-218]\] and Pottegard et al. \[[@b18-kjim-2019-218]\] reported that cumulative doses of HCTZ were associated with increased risk of NMSC and SCC lip cancer, respectively. In contrast, a meta-analysis study by Gandini et al. \[[@b21-kjim-2019-218]\] showed no significant increase in the risk of skin cancer in thiazide users, and a Danish cohort study by Kaae et al. \[[@b22-kjim-2019-218]\] found no association between long-term daily use of bendroflumethiazide and increased risk of skin cancer. However, the two Danish studies were not statistically adjusted for concurrent use of other antihypertensive drugs that may have photosensitizing properties; the studies also have the possibility of selection bias and diagnostic bias from challenges associated with case-control studies \[[@b31-kjim-2019-218]\]. The meta-analyses might have underestimated the association between drug use and skin cancer with differences in the definition of exposure to the drugs and the diversity of study designs among multiple studies. In addition, these studies focused on a wide range of hypertensive drugs rather than focusing on HCTZ alone; thus, they do not accurately represent the association between skin cancer risk and use of HCTZ. As these epidemiological studies offer inconsistent results of the association between diuretics including HCTZ and the risk of skin cancer with some limitations, whether HCTZ use increases the risk of skin cancer remains controversial.

The strengths of the current study include the population-based design and large sample size based on nationwide registries with accurate information, including prescription data, medical conditions, and skin or other cancer diagnoses, thus minimizing the possibility of selection and information bias. In the statistical analyses in this study, comorbidities and a number of concurrent medications including immunosuppressant agents (cyclosporine A, azathioprine, mycophenolate mofetil), photosensitizing drugs, and other drugs potentially affecting skin cancer were adjusted for potential confounders. In addition, by defining HCTZ-users as those with at least three prescriptions, the effects of drug compliance and prescription code errors are minimized. The possibility of diagnostic bias was also minimized by using cohorts of hypertensive patients. Based on these strengths, we propose that our study shows reliability and provides valuable results in clarifying the association of HCTZ use and skin cancer.

There may be several explanations for our findings that showed the decreased risk of skin cancer with HCTZ use. First, differences of race/ethnicity of the study population may explain the contradictory results with previous studies. Korea has a lower incidence of skin cancer and different baseline risk of skin cancer compared with Western countries, including geographic variation (latitude), skin phenotype, and lifestyle for sun exposure \[[@b3-kjim-2019-218],[@b4-kjim-2019-218],[@b6-kjim-2019-218],[@b7-kjim-2019-218],[@b10-kjim-2019-218],[@b14-kjim-2019-218]\]. Most Koreans have a lifestyle that is less prone to UV exposure and a Fitzpatrick skin phenotype III (55.0% to 78.9%) and IV (29.0%), resulting in less sunburn potential than the Western population \[[@b8-kjim-2019-218],[@b32-kjim-2019-218]\]. This reduced UV exposure may reduce the intensity of the photosensitizing properties of HCTZ, which are considered as the possible mechanism for the risk of skin cancer. Second, the anti-cancer activity of HCTZ may have counteracted or overwhelmed the potential carcinogenetic effects of photosensitivity of HCTZ. Although photosensitizing property of HCTZ is well known, little is known about the possible anti-cancer properties of HCTZ. HCTZ may exert antioxidative effects from direct inhibition of vascular NADPH oxidase activity and reduce matrix metalloproteinase 2 (MMP-2) levels and activity \[[@b33-kjim-2019-218]-[@b35-kjim-2019-218]\]. MMPs play a role in tumor progression by enhancing tumor-induced angiogenesis and breakdown of extracellular matrix, resulting in the destruction of local tissue architecture and basement membranes to allow tumor invasion and metastasis in NMSC and melanoma \[[@b34-kjim-2019-218],[@b36-kjim-2019-218]\]. O'Grady et al. \[[@b37-kjim-2019-218]\] reported that increased expression of MMPs are related to the depth of lesion, inflammation, and microvessel density in NMSC and may be useful indicators of cutaneous cancer invasion and progression. Therefore, we postulate that the anti-cancer activities of HCTZ, through its antioxidative and MMP inhibitory effects, may have counteracted the photosensitizing effects and contributed to the overall decrease in the risk of skin cancer in HCTZ-users.

This study also has some limitations. First, the NMSC cases were not divided into SCC and BCC because of the heterogeneity of C44 (other malignant neoplasm of skin), so the association between the use of HCTZ and BCC and SCC could not be examined. Second, UV exposure have been reported to increase the risk of skin cancer also in Korean, but as our study was register-based, we did not have access to individual-level data on history of UV exposure and skin phenotype \[[@b38-kjim-2019-218]\]. However, this study was conducted in a homogeneous study population with similar race/ethnicity, and thus we presume that UV exposure and skin phenotypes can be regarded as not markedly different between HCTZ-users and non-HCTZ-users. Lastly, due to the limited availability of mortality rate from HIRA database, death rate during the follow-up period could not be evaluated as a confounding factor in this study. This is the original study about the association with the use of HCTZ and the risk of skin cancers in Asian population and suggests a protective effect of HCTZ against skin cancer. As our study shows contrary findings to previous studies, further population- and ethnicity-based epidemiological studies of HCTZ will be needed to elucidate the association between HCTZ and the risk of skin cancer.

In conclusion, the use of HCTZ seems to have a chemopreventive effect against NMSC and melanoma in a Korean population. High cumulative doses (≥ 50,000 mg) of HCTZ may decrease the risk of both melanoma and NMSC in South Korea.

KEY MESSAGE
===========

1\. Hydrochlorothiazide has a photosensitizing property, and recent studies reported that hydrochlorothiazide was associated with an increased risk of skin cancer in Western countries.

2\. In this study, cumulative use of hydrochlorothiazide was associated with decreased risk of skin cancer with clear cumulative dose-response and duration-response relationship.

3\. Use of hydrochlorothiazide may have a chemopreventive effect against skin cancer in Korean.
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![The stepwise approach for patient selection. HIV, human immunodeficiency virus; AZA, azathioprine; CsA, cyclosporine A; MMF, mycophenolate mofetil; HCTZ, hydrochlorothiazide; NMSC, non-melanoma skin cancer. ^a^Having at least three prescriptions of HCTZ prior to the first diagnosis of skin cancer (NMSC, melanoma) or on June, 30, 2017.](kjim-2019-218f1){#f1-kjim-2019-218}

![(A) Dose-response and (B) duration-response patterns of hydrochlorothiazide (HCTZ) and the risk of non-melanoma skin cancer (NMSC) and melanoma. Error bars represent 95% confidence intervals.](kjim-2019-218f2){#f2-kjim-2019-218}

###### 

Characteristics of study subjects according to types of skin cancer

  Characteristic                                                                            NMSC             Melanoma                                                                                                         
  ----------------------------------------------------------------------------------------- ---------------- ------------------ --------------------------------------------------------- ---------------- ------------------ ---------------------------------------------------------
  Age, yr                                                                                   55.8 ± 12.7      55.1 ± 12.9        \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   55.8 ± 12.7      55.1 ± 12.9        \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
  Age_groups, yr                                                                                                                                                                                                              
   18--34                                                                                   44,664 (3.4)     85,918 (4.6)                                                                 44,664 (3.4)     85,918 (4.6)       
   35--49                                                                                   393,682 (29.7)   539,033 (29.1)                                                               393,707 (29.7)   539,033 (29.1)     
   50--64                                                                                   552,018 (41.6)   800,226 (43.2)                                                               552,092 (41.6)   800,226 (43.2)     
   ≥ 65                                                                                     336,892 (25.4)   426,185 (23.0)                                                               337,210 (25.4)   426,185 (23.0)     
  Sex                                                                                                                           \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^                                       \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Male                                                                                     693,107 (52.2)   1,089,555 (58.9)                                                             693,265(52.2)    1,089,555 (58.9)   
   Female                                                                                   634,149 (47.8)   761,807 (41.1)                                                               634,408 (47.8)   761,807 (41.1)     
  Charlson comorbidity index score                                                                                                                                                                                            
   0 (low)                                                                                  70,990 (5.3)     118,303 (6.4)                                                                70,991 (5.3)     118,303 (6.4)      
   1--2 (medium)                                                                            401,867 (30.3)   628,634 (34.0)                                                               401,866 (30.3)   628,634 (34.0)     
   ≥ 3 (high)                                                                               854,399 (64.4)   1,104,425 (59.7)                                                             854,816 (64.4)   1,104,425 (59.7)   
  Concurrent use of photosensitizing drugs^[b](#tfn2-kjim-2019-218){ref-type="table-fn"}^                                                                                                                                     
   Amlodipine                                                                               763,125 (57.5)   1,062,828 (57.4)   0.116                                                     763,508 (57.5)   1,063,077 (57.4)   0.127
   Losartan                                                                                 620,168 (46.7)   383,786 (20.7)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   620,399 (46.7)   383,869 (20.7)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Valsartan                                                                                417,282 (31.4)   389,835 (21.1)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   417,527 (31.4)   389,958 (21.1)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Telmisartan                                                                              284,014 (21.4)   281,247 (15.2)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   284,144 (21.4)   281,305 (15.2)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Olmesartan                                                                               262,594 (19.8)   220,217 (11.9)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   262,736 (19.8)   220,282 (11.9)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Candesartan                                                                              153,248 (11.5)   121,081 (6.5)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   153,317 (11.5)   121,119 (6.5)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Glimepiride                                                                              142,651 (10.7)   155,995 (8.4)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   142,729 (10.8)   156,042 (8.4)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Carvedilol                                                                               122,643 (9.2)    134,532 (7.3)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   122,718 (9.2)    134,581 (7.3)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Levofloxacin                                                                             121,231 (9.1)    121,145 (6.5)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   121,939 (9.1)    121,238 (6.5)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Celecoxib                                                                                119,071 (9.0)    108,138 (5.8)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   119,317 (9.0)    108,333 (5.9)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Ciprofloxacin                                                                            106,527 (8.0)    106,308 (5.7)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   106,656 (8.0)    106,401 (5.7)      \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
  Concurrent use of other drugs affecting skin cancer                                                                                                                                                                         
   Atorvastatin                                                                             420,486 (31.7)   481,284 (26.0)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   420,739 (31.7)   481,455 (26.0)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Aspirin                                                                                  392,984 (29.6)   433,731 (23.4)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   393,232 (29.6)   433,896 (23.4)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Methylprednisolone                                                                       377,704 (28.5)   404,495 (21.8)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   378,087 (28.5)   404,742 (21.9)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Prednisolone                                                                             350,951 (26.4)   346,590 (18.7)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   351,308 (26.5)   346,775 (18.7)     \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^
   Simvastatin                                                                              83,777 (6.3)     67,847 (3.7)       \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^   83,823 (6.3)     67,867 (3.7)       \< 0.001^[a](#tfn1-kjim-2019-218){ref-type="table-fn"}^

Values are presented as mean ± SD or number (%).

NMSC, non-melanoma skin cancer; HCTZ, hydrochlorothiazide.

*p* \< 0.05 for HCTZ-users versus non-HCTZ users.

Only some of the concurrently administered photosensitizing drugs are listed in order of frequency.

###### 

The incidence rate and hazard ratios of NMSC and melanoma in HCTZ users versus non-HCTZ users

  Variable                          Event of skin cancer   Follow-up, PY   The incidence of 100,000 PY (95% CI)   Adjusted HR (95% CI)^[a](#tfn3-kjim-2019-218){ref-type="table-fn"}^   *p* value                                                 Fully-adjusted HR (95% CI)^[b](#tfn4-kjim-2019-218){ref-type="table-fn"}^   *p* value
  --------------------------------- ---------------------- --------------- -------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------
  NMSC                                                                                                                                                                                                                                                                                                                        
   Non-HCTZ users (n = 1,851,362)   2,811                  8,355,577.42    33.64 (32.41--34.91)                   1 (Ref)                                                                                                                         1 (Ref)                                                                     
   HCTZ users (n = 1,327,256)       2,115                  7,541,132.52    28.04 (26.86--29.27)                   0.72 (0.68--0.77)                                                     \< 0.001^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^   0.96 (0.91--1.02)                                                           0.236
   Cumulative doses of HCTZ, mg                                                                                                                                                                                                                                                                                               
    Non-user                        2,811                  8,355,577.42    33.64 (32.41--34.91)                   1 (Ref)                                                                                                                         1 (Ref)                                                                     
    Low user (\< 50,000)            2,106                  7,429,752.40    28.35 (27.15--29.58)                   0.73 (0.69--0.77)                                                     \< 0.001^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^   0.97 (0.92--1.04)                                                           0.499
    High user (≥ 50,000)            9                      111,380.13      8.08 (3.69--15.34)                     0.20 (0.10--0.38)                                                     \< 0.001^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^   0.22 (0.11--0.42)                                                           \< 0.001^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^
  Melanoma                                                                                                                                                                                                                                                                                                                    
   Non-HCTZ users (n = 1,851,362)   706                    8,360,968.10    8.44 (7.83--9.09)                      1 (Ref)                                                                                                                         1 (Ref)                                                                     
   HCTZ users (n = 1,327,673)       460                    7,547,814.32    6.09 (5.55--6.68)                      0.63 (0.56--0.71)                                                     \< 0.001^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^   0.85 (0.75--0.97)                                                           0.016^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^
   Cumulative doses of HCTZ, mg                                                                                                                                                                                                                                                                                               
    Non-user                        706                    8,360,968.10    8.44 (7.83--9.09)                      1 (Ref)                                                                                                                         1 (Ref)                                                                     
    Low user (\< 50,000)            458                    7,436,256.36    6.16 (5.61--6.75)                      0.64 (0.57--0.72)                                                     \< 0.001^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^   0.87 (0.77--0.99)^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^            0.031^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^
    High user (≥ 50,000)            2                      111,557.96      1.79 (0.22--6.48)                      0.18 (0.04--0.70)                                                     0.014^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^      0.20 (0.05--0.79)^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^            0.022^[c](#tfn5-kjim-2019-218){ref-type="table-fn"}^

NMSC, non-melanoma skin cancer; HCTZ, hydrochlorothiazide; PY, person-year; CI, confidence interval; HR, hazard ratio.

Adjusted for age, sex, and Charlson comorbidity index scores (0, low; 1 to 2, medium; ≥ 3, high).

Adjusted for age, sex, Charlson comorbidity index scores (0, low; 1 to 2, medium; ≥ 3, high), concurrent use of photosensitizing drugs, and concurrent use of drugs potentially affecting skin cancer.

*p* \< 0.05 for HCTZ-users versus non-HCTZ users.

###### 

Relation of exposure to HCTZ and the risk of NMSC and melanoma according to doses and duration of HCTZ use

  Variable   Event of skin cancer                          PY of follow-up                                                      The incidence of 100,000 PY (95% CI)   Adjusted HR (95% CI)^[a](#tfn6-kjim-2019-218){ref-type="table-fn"}^   *p* value              Fully-adjusted HR (95% CI)^[b](#tfn7-kjim-2019-218){ref-type="table-fn"}^   *p* value                                                                                                            
  ---------- --------------------------------------------- -------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------- ---------------------- --------------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------
  NMSC                                                                                                                                                                                                                                                                                                                                                                                                                                                               
             Cumulative doses of HCTZ, mg                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                           \< 10,000                                                            1,457                                  4,115,410.45                                                          35.40 (33.61--37.27)   1 (Ref)                                                                                                                                1 (Ref)                                                   
                                                           10,000--29,999                                                       592                                    2,765,529.45                                                          21.40 (19.72--23.20)   0.67 (0.61--0.73)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.66 (0.60--0.72)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           30,000--49,999                                                       57                                     548,812.50                                                            10.38 (7.87--13.46)    0.30 (0.23--0.39)                                                           \< 0.001 ^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   0.27 (0.20--0.34                                          \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           ≥ 50,000                                                             9                                      111,380.13                                                            8.08 (3.69--15.34)     0.22 (0.11--0.42)                                                           \< 0.001 ^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   0.18 (0.09--0.34)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           *p* value for trend^[d](#tfn9-kjim-2019-218){ref-type="table-fn"}^                                                                                                                                       \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^                                                                                \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   
             Cumulative doses of HCTZ, quartiles (range)                                                                                                                                                                                                                                                                                                                                                                                                             
                                                           Quartile 1 (3.125--2,699.99 mg)                                      722                                    1,771,008.10                                                          40.76 (37.85--43.85)   1 (Ref)                                                                                                                                1 (Ref)                                                   
                                                           Quartile 2 (2,700.0--7,268.74 mg)                                    538                                    1,678,673.06                                                          32.04 (29.40--34.88)   0.90 (0.81--1.01)                                                           0.075                                                      0.97 (0.87--1.09)                                         0.599
                                                           Quartile 3 (7,268.75--16,487.49 mg)                                  524                                    1,861,409.44                                                          28.15 (25.79--30.67)   0.81 (0.72--0.91)                                                           \< 0.001 ^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   0.87 (0.77--0.97)                                         0.013^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           Quartile 4 (16,487.50--8,332,212.5 mg)                               331                                    2,230,041.93                                                          14.84 (13.29--16.53)   0.43 (0.37--0.49)                                                           \< 0.001 ^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   0.41 (0.36--0.47)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           *p* value for trend^[d](#tfn9-kjim-2019-218){ref-type="table-fn"}^                                                                                                                                       \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^                                                                                \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   
             Cumulative duration of HCTZ use, yr                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                           \< 1                                                                 1,085                                  2,726,686.18                                                          39.79 (37.46--42.23)   1 (Ref)                                                                                                                                1 (Ref)                                                   
                                                           1-- \< 2                                                             385                                    1,357,939.56                                                          28.35 (25.59--31.33)   0.81 (0.72--0.91)                                                           0.004^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^       0.85 (0.76--0.96)                                         0.011^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           2-- \< 3                                                             264                                    942,081.32                                                            28.02 (24.74--31.62)   0.80 (0.70--0.91)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.83 (0.72--0.95)                                         0.009^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           3-- \< 4                                                             174                                    735,840.37                                                            23.64 (20.26--27.43)   0.68 (0.58--0.80)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.69 (0.59--0.81)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           4-- \< 5                                                             101                                    620,525.22                                                            16.27 (13.26--19.78)   0.48 (0.39--0.59)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.46 (0.37--0.57)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           5-- \< 6                                                             58                                     500,281.54                                                            11.59 (8.80--14.99)    0.34 (0.26--0.45)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.31 (0.24--0.41)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           6-- \< 7                                                             37                                     388,410.07                                                            9.52 (6.71--13.13)     0.28 (0.20--0.39)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.24 (0.17--0.33)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           7-- \< 8                                                             11                                     219,494.99                                                            5.01 (2.50--8.97)      0.14 (0.08--0.25)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.11 (0.06--0.20)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           ≥ 8                                                                  0                                      49,872.28                                                             0.00 (0.00--7.40)      0                                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0                                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           *p* value for trend^[d](#tfn9-kjim-2019-218){ref-type="table-fn"}^                                                                                                                                       \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^                                                                                \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   
  Melanoma                                                                                                                                                                                                                                                                                                                                                                                                                                                           
             Cumulative doses of HCTZ, mg                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                           \< 10,000                                                            323                                    4,118,700.67                                                          7.84 (7.01--8.75)      1 (Ref)                                                                                                                                1 (Ref)                                                   
                                                           10,000--29,999                                                       124                                    2,767,974.92                                                          4.48 (3.73--5.34)      0.61 (0.50--0.75)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.59 (0.48--0.73)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           30,000--49,999                                                       11                                     549,580.76                                                            2.00 (1.00--3.58)      0.25 (0.14--0.45)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.22 (0.12--0.40)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           ≥ 50,000                                                             2                                      111,557.96                                                            1.79 (0.22--6.48)      0.21 (0.05--0.85)                                                           0.030^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^       0.17 (0.04--0.68)                                         0.012^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           *p* value for trend^[d](#tfn9-kjim-2019-218){ref-type="table-fn"}^                                                                                                                                       \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^                                                                                \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   
             Cumulative doses of HCTZ, quartiles (range)                                                                                                                                                                                                                                                                                                                                                                                                             
                                                           Quartile 1 (3.125--2,699.99 mg)                                      163                                    1,772,766.88                                                          9.19 (7.84--10.72)     1 (Ref)                                                                                                                                1 (Ref)                                                   
                                                           Quartile 2 (2,700.0--7,274.99 mg)                                    125                                    1,682,317.55                                                          7.43 (6.18--8.85)      0.90 (0.72--1.14)                                                           0.397                                                      0.94 (0.75--1.20)                                         0.669
                                                           Quartile 3 (7,275.00--16,499.99 mg)                                  109                                    1,876,604.76                                                          5.81 (4.77--7.01)      0.72 (0.56--0.91)                                                           0.007^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^       0.74 (0.58--0.95)                                         0.018^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           Quartile 4 (16,500.00--8,332,212.5 mg)                               63                                     2,216,125.09                                                          2.84 (2.18--3.64)      0.34 (0.25--0.46)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.31 (0.23--0.42)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           *p* value for trend^[d](#tfn9-kjim-2019-218){ref-type="table-fn"}^                                                                                                                                       \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^                                                                                \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   
             Cumulative duration of HCTZ use, yr                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                           \< 1                                                                 246                                    2,729,071.66                                                          9.01 (7.92--10.21)     1 (Ref)                                                                                                                                1 (Ref)                                                   
                                                           1--\< 2                                                              86                                     1,358,918.28                                                          6.33 (5.06--7.82)      0.78 (0.61--0.99)                                                           0.044^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^       0.80 (0.63--1.03)                                         0.094
                                                           2--\< 3                                                              56                                     942,699.29                                                            5.94 (4.49--7.71)      0.72 (0.54--0.97)                                                           0.030^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^       0.74 (0.55--0.99)                                         0.047^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           3--\< 4                                                              35                                     736,452.51                                                            4.75 (3.31--6.61)      0.58 (0.41--0.83)                                                           0.002^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^       0.57 (0.40--0.82)                                         0.003^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           4--\< 5                                                              16                                     621,125.10                                                            2.58 (1.47--4.18)      0.32 (0.19--0.53)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.30 (0.18--0.50)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           5--\< 6                                                              14                                     500,844.52                                                            2.80 (1.53--4.69)      0.34 (0.20--0.59)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.31 (0.18--0.53)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           6--\< 7                                                              4                                      388,886.84                                                            1.03 (0.28--2.63)      0.12 (0.05--0.33)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.10 (0.03--0.28)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           7--\< 8                                                              3                                      219,844.21                                                            1.36 (0.28--3.99)      0.15 (0.05--0.47)                                                           \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^    0.12 (0.03--0.38)                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           ≥ 8                                                                  0                                      49,971.90                                                             0.00 (0.00--7.38)      0                                                                                                                                      0                                                         \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^
                                                           *p* value for trend^[d](#tfn9-kjim-2019-218){ref-type="table-fn"}^                                                                                                                                       \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^                                                                                \< 0.001^[c](#tfn8-kjim-2019-218){ref-type="table-fn"}^   

NMSC, non-melanoma skin cancer; HCTZ, hydrochlorothiazide; PY, person-year; CI, confidence interval; HR, hazard ratio.

Adjusted for age, sex, and Charlson comorbidity index scores (0, low; 1 to 2, medium; ≥ 3, high).

Adjusted for age, sex, Charlson comorbidity index scores (0, low; 1 to 2, medium; ≥ 3, high), concurrent use of photosensitizing drugs, and concurrent use of drugs potentially affecting skin cancer.

*p* \< 0.05 for HCTZ-users versus non-HCTZ users.

*p* value for trend was calculated using the likelihood ratio.
